Vanguard Group Inc Annovis Bio, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 357,942 shares of ANVS stock, worth $2.97 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
357,942
Previous 337,354
6.1%
Holding current value
$2.97 Million
Previous $6.31 Million
32.48%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ANVS
# of Institutions
52Shares Held
1.2MCall Options Held
779KPut Options Held
1.77M-
Adage Capital Partners Gp, L.L.C. Boston, MA250KShares$2.08 Million0.01% of portfolio
-
Black Rock Inc. New York, NY97.6KShares$811,2960.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA72.6KShares$603,3220.0% of portfolio
-
Geode Capital Management, LLC Boston, MA70.8KShares$588,2730.0% of portfolio
-
Wescott Financial Advisory Group, LLC41.6KShares$345,7540.07% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $67.8M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...